Antimicrobial resistance Archives

mutabilis novo holdings antibiotic resistance

News and Trends 6 Jan 2020

€5M Investment to Fund French Biotech’s Resistance-Busting Antibiotic

Mutabilis has received a €5M investment from the Danish VC Novo Holdings’ REPAIR Impact Fund to fuel the development of a new class of antibiotics that could kill drug-resistant strains of gram-negative bacteria. The French company will use the money to advance one of its preclinical drugs, a wide-spectrum intravenous antibiotic, to clinical trials. The […]

January 6, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 3 Jan 2020

Update: CARB-X Grants Antabio Additional €4M to Develop Cystic Fibrosis Antibiotic

Update (03/01/2020): The global non-profit partnership CARB-X has awarded Antabio €4M ($4.4M) as a second grant installment funding development of a novel antibiotic for use against Pseudomonas infections in patients with cystic fibrosis. This is the second installment of a grant worth up to €7.6M awarded to Antabio in 2017. The French biotech was awarded […]

January 3, 2020 - 2 minutesmins - By Clara Rodríguez Fernández

antibiotic resistance iterum therapeutics

News and Trends 12 Dec 2019

Iterum Therapeutics Reels from Antibiotic Phase III Fail

An antibiotic candidate developed by the Irish company Iterum Therapeutics has failed to meet the main goal of a phase III trial, a blow for efforts to meet the challenge of global antibiotic resistance. Iterum Therapeutics’ drug sulopenem was tested in a phase III trial that recruited 674 patients suffering from complicated intra-abdominal infections. These […]

December 12, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 25 Oct 2019

EU Court Ushers in the Use of Phages Against Listeria in Food

Amidst recent listeria outbreaks in Europe, the European Court of Justice has issued a court order in favor of the company Micreos Food Safety allowing the use of its phage technology to keep listeria at bay in food. Bacteriophages, or phages for short, are viruses that only kill specific bacterial strains and are harmless to […]

October 25, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Oct 2019

Austrian Biotech Will Develop Viral Protein For Vaginal Infection

The Austrian biotech company PhagoMed Biopharma is developing a viral protein that could one day treat the common condition bacterial vaginosis without disrupting the microbiome as traditional antibiotics do. The preclinical drug candidate is derived from a protein called an endolysin. Endolysins are made by bacteria-hunting viruses called bacteriophages and kill bacteria by rupturing the […]

October 22, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 17 Sep 2019

UK Biotech to Fight Antibiotic-Resistant Bacteria with €8M Grant

The UK biotech Procarta Biosystems has received a grant worth up to €8.3M from the nonprofit US partnership CARB-X to develop drugs that kill antibiotic-resistant pathogens while sparing benign bacteria in the gut. The total funding includes €2M upfront and up to an extra €6.3M that Procarta will receive if it hits unspecified milestones. Procarta […]

September 17, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 4 Sep 2019

US Genomics Firm Combines with Curetis to Tackle Antibiotic Resistance

The German biotech Curetis has been combined with the US genomics company OpGen to pool their molecular diagnostics expertise in the fight against antibiotic resistance. “After more than one year of intensive discussions and negotiations for many months, it feels great to be able to announce the transaction today,” Oliver Schacht, the CEO of Curetis, […]

September 4, 2019 - 3 minutesmins - By Jonathan Smith

Nabriva story bacterial pneumonia antibiotic

News and Trends 20 Aug 2019

Nabriva Therapeutics Gets FDA Green Light for Pneumonia Antibiotic

The US FDA has approved Nabriva Therapeutics’ Xenleta for treating community-acquired bacterial pneumonia, the first in a new class of antibiotics developed to treat this condition. Xenleta, also known as lefamulin, was discovered almost 10 years ago by Nabriva Therapeutics, a spinout company from Novartis split between Austria, Ireland and the US. The approval is […]

August 20, 2019 - 3 minutesmins - By Helen Albert

pneumonia polyphor antibiotic murepravadin

More News! 18 Jul 2019

Swiss Pneumonia Antibiotic Abandoned in Phase III

The Swiss biotech Polyphor has discontinued two phase III trials of its antibiotic for treating pneumonia after halting both trials due to safety concerns in May. The two phase III trials were testing Polyphor’s intravenous antibiotic murepavadin in hospitalized patients with pneumonia. In May, Polyphor halted the two trials due to an unexpectedly high incidence […]

July 18, 2019 - 2 minutesmins - By Jonathan Smith

anthrax treatment belgium VIB nanobodies

More News! 17 Jul 2019

Scientists in Belgium Cure Anthrax in Mice by Smashing Bacteria’s Armor

Belgian researchers have developed a potential treatment for anthrax that breaks down the bacteria’s thick protein armor. Anthrax is a deadly type of bacteria famous for its use in terrorist attacks in 2001. Although anthrax infections can be treated with antibiotics, they can prove hard to treat when the bacteria are inhaled or ingested. Scientists […]

July 17, 2019 - 2 minutesmins - By Jonathan Smith

evotec tuberculosis treatment gates foundation

More News! 12 Jun 2019

Evotec to Reduce the Burden of Tuberculosis Treatment with €21M Grant

The Bill and Melinda Gates Foundation has granted the German biotech Evotec €21M ($23.8M) to discover drug combinations that can reduce the duration of tuberculosis treatment, which normally takes over six months. Evotec will use the money to test different drug combinations for tuberculosis in the preclinical stage. The partnership will last for five years, […]

June 12, 2019 - 2 minutesmins - By Jonathan Smith

mobidiag antibiotic resistance diagnostic

News and Trends 15 May 2019

€25M European Loan to Fund Diagnostics Tackling Antibiotic Resistance

The Finnish biotech Mobidiag has received a loan of €25M from the European Investment Bank to commercialize diagnostic technology aimed at reducing antibiotic resistance. When patients get a bacterial infection, clinicians have to wait several days for traditional diagnosis techniques to tell them what kind of bacteria is causing the infection. While they wait, the […]

May 15, 2019 - 2 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us